chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient reported a bruise at injection site and lump underneath skin starting Saturday (morning after vaccination).  Bruise worsened Sunday morning to size of 1/2 dollar with redness spreading down the arm.  Bruise worsened again Monday morning, slightly in size, with increase redness in addition to pain/burning sensation.  Patient treated with ice Monday afternoon which decreased bruise and redness slightly.
Immediate pain in left upper arm that has continued to this day. The pain started radiating up to the left shoulder and left side of neck over the first 24-48 hours, and has caused increase in migraines from 1 every 2-3 weeks, to now a 14-day migraine and counting. My left upper arm is still sore to the touch. My neck and shoulder have spasms and my neck gets "stuck" when trying to do slow, gentle ROM.
DEATH Narrative: No information available in the record other than date of vaccine on 1/7/2021 with no adverse effects or complications noted during observation period. Patient was not known to have had COVID infection prior to death. Had last received medical care at facility in 2012 except received audiology care up to 12/2/2020. No recent hospitalizations known. No death note or autopsy noted. Only indication of death is the updated banner/date of death in demographics. Death most likely due to advanced age (84 y/o) in addition to comorbidities.
Three days post vax pt developed a rash, nonvesicular, appeared at the MMR injection site, then spread.  102 fever thought to be due to otitis media.
He received the first dose of the covid 19 vaccine noted body aches improved; This is a spontaneous report from a contactable consumer (patient). This is the second of two reports. The first report is a report received by Pfizer . A 53-year-old male patient received his first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number and expiration date were not reported), via an unspecified route of administration on an unspecified date as first dose, single for COVID-19 immunization. The patient's medical history included hypertension from 2011 and body aches. The patient's concomitant medications were not reported. The patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) and noted body aches improved on an unspecified date.   Information on the lot/batch number has been requested.; Sender's Comments: Linked Report(s) : same patient, diff drug/event
I can't stop coughing; loose my voice; This spontaneous case was reported by an other health care professional and describes the occurrence of COUGH (I can't stop coughing) and APHONIA (loose my voice) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COUGH (I can't stop coughing) and APHONIA (loose my voice). At the time of the report, COUGH (I can't stop coughing) and APHONIA (loose my voice) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant information was reported. No treatment information was reported.
After the shot was given, she walked with her mother and sister to sit down for 15 minutes. Before I could get inside the pharmacy my cashier said the little girl is sick. She was sitting in the chair with  her legs stretched, her head was back and her eyes were closed. Her mom and I lifted her on the mat on the floor and her mom and dad kept talking to her to try to arouse her. We placed a cold pack and cool napkins on her forehead and back of her neck. She was pale she opened her eyes but was not talking. She kept closing her eyes and putting her head  back. We kept talking to her and her mom asked her if she knew where she was and she answered pharmacy. The parents did not want to call 911 because this has happened before a long time ago when she cut herself in the shower.  In that previous incident 911 came and  she recovered in about 5 minutes. Today mom and dad said the same thing was happening but this  time was longer than 5 minutes.  She was able to stand on her own with support from  dad and they left with her slowing  walking out.
Patient complained of pain ever since Td administered to right deltoid on 04/03/2003.  Complained of pain, tingling, weakness in right upper arm.  (+) red, swollen right after administration.
Swollen Lynch node (right side of neck).   Gotten smaller, checked out by Dr. when I went back for 2nd dosage
short of breath; a fast heartbeat; dizzy; nauseous; arm was sore at the injection site; fatigue; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of DYSPNOEA (short of breath) in an 87-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (Medical history not provided).   On 03-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form.  On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Mar-2021, the patient experienced DYSPNOEA (short of breath) (seriousness criterion medically significant), HEART RATE INCREASED (a fast heartbeat), DIZZINESS (dizzy), NAUSEA (nauseous), VACCINATION SITE PAIN (arm was sore at the injection site) and FATIGUE (fatigue).   On 05-Mar-2021, FATIGUE (fatigue) had resolved. At the time of the report, DYSPNOEA (short of breath), HEART RATE INCREASED (a fast heartbeat), DIZZINESS (dizzy), NAUSEA (nauseous) and VACCINATION SITE PAIN (arm was sore at the injection site) outcome was unknown.
joint pains to our elbows for 5 weeks; This is a spontaneous report from a contactable consumer. A male patient of an unspecified age received BNT162B2(PFIZER-BIONTECH COVID-19 VACCINE; formulation: Solution for injection; Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date as a 2ND DOSE, SINGLE for covid-19 immunisation. The patient medical history was not reported. The patient received historical vaccine of BNT162B2 (COVID 19 Vaccine) as first dose on an unspecified date. The patient's concomitant medications were not reported. On an unspecified date the patient experienced joint pains in elbows for 5 weeks (arthralgia) (non-serious). The outcome of the event was unknown.  Information on the Lot/Batch number has been requested.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021592717 Same reporter/drug/AE, different patient
Patient has a known seizure disorder and takes Topamax and Zonegron. 5 Minutes after shot had a seizure lasting less than 1 minute and 15 minutes after seizure shot had a seizure lasting less than one minute.
Syncope at approximately 3:10 AM, syncope at approximately 3:15 AM, fever of 101 degrees Fahrenheit through approximately 2PM of March 1 2008 (down to 100 degrees thereafter).  Treatment:  aspirin, fluids.
Moderna second dose given 14 days too soon.  No adverse reactions, no reactions during recommended wait time after administering vaccine.
Next morning red and firm at site of injection. reported that pain lasted a long time. Pt reports the shot made her "unsteady" ever since receiving and has fallen numerous times once resulting in fracture of hand.
Pt is a 19 y/o F who suddenly endorsed feeling dizzy, hot, short of breathe, and peri-oral itchiness ~ 10min after receiving first dose of Pfizer vaccine (done at 1357). PMHx pertinent for hx of anaphylaxis to bee stings, currently being treated with allergy shots, last injections given 12JUL21. Pt was immediately evaluated, with initial VS done at 1415 with BP 110/70, SPO2 99%, HR of 94, RR >20. Endorse chest tightness. Lungs CTA B/L, pt noted to be diaphoretic. Patient had a near syncopal episode and was placed in supine position and given an epi-pen 0.3mg at 1418. EMS was called. Repeat VS at 1420 found BP of 115/60, SpO2 100%, HR 100, RR >20. Lungs still CTA b/l.  Patient endorsed improved SOB and less peri-oral itching. Chest tightness improved, Pt was AOX3. EMS arrived at 1435, pt stable. Transferred pt to EMS.
Muscle aches, nausea, stomach pains, gas diarrhea, dizziness, weakness have had to stay near bed and bathroom for 5 days, continuing, difficult to keep food down--or up.  No cough or 'head cold'.
Vaccination error: The patient's first vaccine was Moderna but received Pfizer for the second dose.
LOSS OF MOTOR FUNCTION OF ARM, PAIN BELOW INJECTION SITE, CONTINOUS SWELLING FOR 3+ WEEKS FOLLOWING VACCINATION
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient of unknown age. No information was provided regarding concomitant medications, concurrent conditions or medical history. On an unknown date in 2015, the patient was inoculated with ZOSTAVAX by a physician as recommended for routine adult health maintenance for the prevention of shingles (dose, route, and lot # not provided). The vaccine did not prevent shingles as intended and the patient subsequently contracted a persistent strain condition of herpes zoster. On an unknown date in 2016, the patient was treated in the center for a blistering vesicular outbreak, which was diagnosed as herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient had suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. On 18-JAN-2018, the patient passed away. Cause of death was unknown. It was unknown if autopsy was performed. Outcome of the events was unknown. Causality assessment was related. Additional information has been requested.
the minimum temperature of the refrigerator reached 29.1 degrees fahrenheit/excursion lasted for 2 hours and 20 minutes with no reported adverse event; Menactra was given to patient post excursion with no reported adverse event; Initial information received on 27-Jul-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 13 years old male patient  and it was reported that the minimum temperature of the refrigerator reached 29.1 degrees fahrenheit/excursion lasted for 2 hours and 20 minutes with no reported adverse event for the vaccine MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA] and Menactra was given to patient post excursion with no reported adverse event vaccine   The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 26-Jul-2022, the patient received a  first dose of 0.5 ml of  suspect MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE, once,  (lot: U7483AB; 20-Oct-2023)  via intramuscular route in the left arm for immunization and tuberculin test (TB test).   On an unknown date , the minimum temperature of the refrigerator reached 29.1 degrees fahrenheit/excursion lasted for 2 hours and 20 minutes with no reported adverse event (product storage error) (latency: unknown) . The data logger did not go off.  The patient was administered the vaccine of MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE post excursion (onset date: 26-Jul-2022; latency: same day)  Action taken: not applicable.  Outcome: unknown   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Vials were reconstituted with only 0.8 mL of NS and three doses drawn from each vial, as opposed to the correct use of 1.8 mL of NS as the diluent.  Patient who received this incorrect dose did not experience any side effects. Patient has been notified as this incident.
She was given the Pfizer vaccination in the left deltoid muscle.   During her 15 minute waiting period after the injection, the patient began to experience localized tingling at the injection site that radiated into her 4th and 5th digits and proximally along the sternomastoid muscle.  She denied rash, hives, difficulty breathing, difficulty swallowing, wheezing, throat tightness, hoarseness, stridor, itching, dizziness, facial swelling, lip swelling and tongue swelling.   This provider was notified of patient reaction and she was then assessed in the emergency bay area. Monitored patient for severe reaction symptoms, including rapid progression of symptoms, vomiting, hypotension and chest pain. Patient was observed for approximately 30 minutes post injection with no evolution of sx. Injection site tingling that extended along the ulnar nerve distribution was improving at the time of discharge.
productive cough, shortness of breath when coughing-Positive covid (symptoms for about a week; positive COVID test on 10/15/21), some headaches, sore throat, body aches, loss of smell.  symptoms starting 10/12/21
Information has been received from a nurse practitioner concerning a female patient who (Sometime in 2010) was vaccinated with a first and a second dose of GARDASIL (Doses, and Lot # not reported), IM. The nurse stated that "sometime in 2010" the patient tested positive for human papilloma virus test (HPV) after being administered either the first and the second dose of GARDASIL. At the time of the report the patient's outcome was unknown. It was unspecified if the patient sought medical attention. Additional information has been requested.
Nauseous, vomiting and headache. Off and on since 2:00 P.M. into night.
No adverse effects were reported; the patient was administered a dose of PROQUAD instead of MMR II; the patient was administered a dose of PROQUAD instead of MMR II; This spontaneous report has been received from a nurse concerning to a 15-months-old patient of unknown gender.  The patient's concurrent conditions, medical history, past drug reactions or allergies and concomitant medications were not reported.  On 23-JUL-2019, the patient received one dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) and varicella virus vaccine live (Oka/Merck) (VARIVAX) using sterile diluent for reconstitution (dose number, route of administration, anatomical location, lot # and expiration date were not reported) for prophylaxis, instead of measles virus vaccine live (Enders-Edmonston), mumps virus vaccine live (Jeryl Lynn), rubella virus vaccine live (Wistar RA 27/3) (M-M-R II) and varicella virus vaccine live (Oka/Merck) (VARIVAX) (interchange of vaccine products) (wrong product administered). No adverse effects were reported.
Difficulty with range of motion, weakness in right arm, pain to injection site. All symptoms began the night of the injection and have not gone away. She was seen by her provider on 11/16/2020, X-rays ordered. Physical therapy referral was made, diclofenac prescribed.
Information has been received from a medical assistant concerning a 15 year old female patient who on an unspecified date was vaccinated with her third dose of GARDASIL (lot # 661953/1130X) and a dose of RECOMBIVAX HB (manufacturer unknown). Concomitant vaccination included Poliovirus vaccine and Influenza virus vaccine (unspecified). After receiving GARDASIL the patient experienced seizures. Unspecified medical attention was sought. Upon internal review, seizure was determined to be an other important medical event. This is one of several reports from the same source. Additional information has been requested.
Patient described a cold sweat and chills, then he lost consciousness and his neighbors called EMS.  He was seen at Hospital.  In the aftermath, the patient complains of hearing loss.
The Pfizer vaccine was diluted with sterile water instead of normal saline and administered to the patient.
arm pain; Lingering Fatigue; Sporadic headache; BACK PAIN; INSOMNIA; cough; Low grade temp; Worn out; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (arm pain), FATIGUE (Lingering Fatigue), HEADACHE (Sporadic headache), BACK PAIN (BACK PAIN) and INSOMNIA (INSOMNIA) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Crohn's disease, Diverticulitis, Diabetes mellitus (controlled type 2 diabetic.) and Immunosuppression. Concomitant products included USTEKINUMAB (STELARA) for Immunosuppression.    On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (arm pain), FATIGUE (Lingering Fatigue), HEADACHE (Sporadic headache), BACK PAIN (BACK PAIN), INSOMNIA (INSOMNIA), COUGH (cough), PYREXIA (Low grade temp) and FATIGUE (Worn out). At the time of the report, PAIN IN EXTREMITY (arm pain), FATIGUE (Lingering Fatigue), HEADACHE (Sporadic headache), BACK PAIN (BACK PAIN), INSOMNIA (INSOMNIA), COUGH (cough), PYREXIA (Low grade temp) and FATIGUE (Worn out) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 21-Jan-2021, COVID-19: positive (Positive) Positive Covid -19 Test.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.
This spontaneous report was received from a registered nurse refers to unknown number of patients of unknown demographics. No relevant medical history of the patients was reported. On an unknown date in 2014, the patients were vaccinated with RECOMBIVAX HB (strength, dose, route of administration, lot number and expiration dates were not reported). No concomitant medications were reported. It was reported that since 18-AUG-2014, unknown number of patients were administered RECOMBIVAX HB which was improperly stored. This was supported. No adverse effects were reported. There was no product quality complaint involved. The outcome was unknown. This is one of several reports from the same source. Additional information has been requested.
pt reported of welts after receiving dose the next day, then rashes that didn't go away quickly. she is ok now and thinks it will resolve by itself.
very dizzy; very tired; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (very dizzy) and FATIGUE (very tired) in an 81-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 006A21A and 014M20A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 (tested positive for COVID-19) on 10-Mar-2021.   On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Mar-2021, the patient experienced DIZZINESS (very dizzy) and FATIGUE (very tired). At the time of the report, DIZZINESS (very dizzy) and FATIGUE (very tired) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 10-Mar-2021, SARS-CoV-2 test: positive (Positive) tested positive for COVID-19.         This case was linked to MOD-2021-061051 (Patient Link).
Fever; Muscle pain; Headache; This case was reported by a consumer and described the occurrence of fever in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, less than 2 years after receiving Shingrix, the patient experienced fever, muscle pain and headache. On an unknown date, the outcome of the fever, muscle pain and headache were unknown.   It was unknown if the reporter considered the fever, muscle pain and headache to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient reported that, after vaccination with dose of shingrix, experienced fever, muscle pain and headache.
having issues with high heart rate still after 8 weeks of the last shot; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of HEART RATE INCREASED (having issues with high heart rate still after 8 weeks of the last shot) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No medical history was provided by the reporter.     On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HEART RATE INCREASED (having issues with high heart rate still after 8 weeks of the last shot). At the time of the report, HEART RATE INCREASED (having issues with high heart rate still after 8 weeks of the last shot) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The patient's medical history was not provided.  patient lab tests data not provided. Concomitant product use was not provided. Treatment information was not provided.   Reporter did not allow further contact
This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. No concurrent conditions or medical history were provided. On an unspecified date in 2016 (reported as "on or after 03-MAR-2016"), the patient was vaccinated with an improperly stored dose of ROTATEQ injection (lot # M002252 with expiry date: 28-FEB-2017, orally; strength, dose and site of administration were unspecified). The administration vaccine underwent temperature excursion at 8.3 degrees Celsius for 19 minutes. There was no previous temperature excursion. It was a case of a "data logger". No concomitant medications were reported. No adverse effect was reported. This is one of several reports from the same source. Additional information has been requested.
Swelling of deltoid muscle from top of shoulder down to mid humerus. No swelling palpable on inferior, inner upper arm. Hot, swollen, tender. No axilla nodes palpated.